Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Therapeutic HIV vaccines are designed to control HIV infection by boosting the body's natural immune response. There are currently no FDA-approved therapeutic HIV vaccines. This study will test whether giving an HIV-1 vaccine together with or without interleukin 12 (IL-12) is safe and effective. This study will also test a new way of giving the vaccine called electroporation (EP).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although highly active antiretroviral therapy (HAART) has greatly reduced HIV infection-related morbidity and mortality, individual response to therapy can be variable. Therapeutic vaccination works by augmenting virus-specific immunity and can be given with or without immunomodulatory agents or adjuvants. In conjunction with HAART, therapeutic vaccination may be a more effective treatment for the suppression of HIV-1 replication. This study will examine the safety and efficacy of giving an investigational vaccine with or without IL-12 in HIV-1 infected adults receiving HAART. This study will also test whether delivering the vaccine using EP is safe and increases the efficacy of the vaccine.

Participation in this study will last approximately 36 weeks. Participants will be randomly assigned to one of five cohorts. Cohort 1 will receive the HIV multi-antigen plasmid DNA (HIV MAG pDNA) vaccine or placebo intramuscularly (IM) in the upper arm followed by EP. Cohorts 2 through 4 will receive the HIV MAG pDNA vaccine and sequentially increasing doses of GENEVAX IL-12 pDNA or placebo by IM/EP. Cohort 5 will receive the HIV MAG pDNA vaccine with the highest dose of IL-12 pDNA or placebo by needle and syringe in the upper arm.

Participants receive two injections at Weeks 0, 4, and 12. Participants will complete a questionnaire that assesses the acceptability of the vaccine and remain at the clinic 30 minutes for observation after each vaccination. Participants will be contacted by telephone 2 to 3 days post-vaccination to assess vaccination-related signs and/or symptoms. All participants will be asked to record their temperatures and any symptoms they experience daily for 4 days following each vaccination on a Vaccination Report Card (VRC). All nonstudy vaccines or medications should also be recorded on the VRC. Study visits will occur at Weeks 0, 1, 2, 4, 5, 6, 8, 12, 13, 14, 16, 24, and 36. At most visits, participants will undergo a physical examination. Women of reproductive potential will also undergo pregnancy testing before receiving injections on Weeks 0, 4, and 12. Blood will be drawn at various time points to evaluate participants' health and measure immunologic markers, CD4 and CD8 T-cell counts, and cytokine levels. Blood and plasma will also be stored for future exploratory studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Interleukin-12 Electroporation HIV Therapeutic Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Intervention Type OTHER

Saline injections at Weeks 0, 4, and 12

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Profectus HIV MAG pDNA vaccine

3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12

Intervention Type BIOLOGICAL

IL-12

Administered at Weeks 0, 4, and 12

Intervention Type BIOLOGICAL

Placebo

Saline injections at Weeks 0, 4, and 12

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-1 infected
* Stable antiretroviral therapy (ART) for a minimum of 6 consecutive months prior to study entry and intention to remain on stable ART until study completion
* CD4 T-cell count greater than or equal to 500 cells/mm3 (within 30 days prior to study entry)
* At least two measurements of HIV-1 RNA levels less than or equal to 200 copies/mL (first measurement must be performed at least 6 months prior to study entry and second measurement must be performed between 6 months prior to study entry and at least 30 days prior to study entry)
* Screening HIV-1 RNA less than 50 copies/mL (within 30 days prior to study entry)
* Hepatitis B surface antigen negative (within 30 days prior to study entry)
* Hepatitis C antibody negative or, if hepatitis C antibody positive, hepatitis C virus RNA negative (within 30 days prior to study entry)
* Certain laboratory values obtained within 30 days prior to study entry; more information can be found in the protocol
* Females of reproductive potential must have a negative urine pregnancy test within 3 days prior to study entry
* All study participants participating in sexual activity that could lead to pregnancy must agree to use at least one of the following forms of birth control for at least 21 days prior to study entry until the final study visit:

* Condoms (male or female) with or without a spermicidal agent
* Diaphragm or cervical cap with spermicide
* Intrauterine device (IUD)
* Hormone-based contraceptive
* Females who are not of reproductive potential are eligible without requiring the use of a contraceptive
* Ability and willingness of subject to provide written informed consent
* Collection of a pre-entry PBMC specimen for immunologic assays and entered into the Laboratory Data Management System (LDMS)

Exclusion Criteria

* Confirmed (defined as two consecutive values) CD4 T-cell count less than 200 cells/mm3 at any time or any history or subject recollection of CD4 T-cell count less than 200 cells/mm3 prior to screening
* Any active malignancy that may require chemotherapy or radiation therapy
* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate IM injection
* A skin-fold measurement of the cutaneous and subcutaneous tissue for eligible injection sites (on the medial deltoid muscles) that exceeds 40 mm
* Use of immunomodulatory, cytokine, or growth stimulating factors such as systemic corticosteroids, cyclosporine, methotrexate, azathioprine, anti-CD25 antibody, granulocyte macrophage colony-stimulating factor (GM-CSF), chondrocyte colony-stimulating factor (C-CSF), IFN, or interleukin-2 (IL-2) (within 30 days prior to study entry)
* Pregnancy or breastfeeding
* Use of any prior HIV vaccine (prophylactic and/or therapeutic) within 1 year before study entry
* Use of any investigational treatment within 6 months before study entry
* Use of any licensed or experimental non-HIV vaccination (e.g., hepatitis B, influenza, pneumococcal polysaccharide) within 4 weeks prior to study entry
* Use of any infusion blood product or immune globulin within 3 months prior to study entry
* Known or suspected hypersensitivity to any vaccine component, including hypersensitivity to amide-type local anesthetics, such as lidocaine (Xylocaine), mepivacaine (Polocaine/Carbocaine), etidocaine (Duranest), bupivacaine (Marcaine), or prilocaine
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
* Serious illness requiring systemic treatment and/or hospitalization within 7 days prior to study entry
* Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillators, nerve stimulators, or deep brain stimulators
* History of cardiac arrhythmia or palpitations (e.g., supraventricular tachycardia, atrial fibrillation, frequent ectopy, or sinus bradycardia \[i.e., \<50 beats per minute on exam\]) prior to study entry (NOTE: Sinus arrhythmia is not excluded)
* History of syncope or fainting episode within 1 year of study entry
* Seizure disorder or any history of prior seizure
* Extensive tattoos covering the site of administration (upper left and right medial deltoid muscles)
* Presence of any surgical or traumatic metal implants at the site of administration (medial deltoid muscles)
* Any chronic inflammatory disease (e.g., ankylosing spondylitis, psoriasis, inflammatory bowel disease)

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey Jacobson, MD

Role: STUDY_CHAIR

Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999 May;5(5):512-7. doi: 10.1038/8394.

Reference Type BACKGROUND

PMID: 10229227 (View on PubMed)

Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650-5. doi: 10.1128/JVI.68.7.4650-4655.1994.

Reference Type BACKGROUND

PMID: 8207839 (View on PubMed)

Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther. 2007 Nov;7(11):1647-64. doi: 10.1517/14712598.7.11.1647.

Reference Type BACKGROUND

PMID: 17961089 (View on PubMed)

Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N; ACTG A5281 Protocol Team. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):163-71. doi: 10.1097/QAI.0000000000000830.

Reference Type DERIVED

PMID: 26761518 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10846

Identifier Type: REGISTRY

Identifier Source: secondary_id

A5281

Identifier Type: -

Identifier Source: org_study_id

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Cohort 1: Vaccine alone IM/EP

Profectus HIV MAG pDNA vaccine

Cohort 1: Placebo

Placebo

Cohort 2: Vaccine plus IL-12 IM/EP

Profectus HIV MAG pDNA vaccine

IL-12

Cohort 2: Placebo

Placebo

Cohort 3: Vaccine plus IL-12 IM/EP

Profectus HIV MAG pDNA vaccine

IL-12

Cohort 3: Placebo

Placebo

Cohort 4: Vaccine plus IL-12 IM/EP

Profectus HIV MAG pDNA vaccine

IL-12

Cohort 4: Placebo

Placebo

Cohort 5: Vaccine plus IL-12 IM

Profectus HIV MAG pDNA vaccine

IL-12

Cohort 5: Placebo

Placebo

Interventions

Profectus HIV MAG pDNA vaccine

IL-12

Placebo

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Responsible Party

Principal Investigators

Jeffrey Jacobson, MD

Locations

UCLA CARE Center CRS

Stanford AIDS Clinical Trials Unit CRS

Ucsf Hiv/Aids Crs

University of Colorado Hospital CRS

Massachusetts General Hospital Clinical Research Site (MGH CRS) CRS

Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS

Washington University Therapeutics (WT) CRS

Trillium Health ACTG CRS

Univ. of Rochester ACTG CRS

Cincinnati CRS

Penn Therapeutics Crs

University of Pittsburgh CRS

Houston AIDS Research Team CRS

Countries

References

Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994 Jul;68(7):4650-5. doi: 10.1128/JVI.68.7.4650-4655.1994.

Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther. 2007 Nov;7(11):1647-64. doi: 10.1517/14712598.7.11.1647.

Other Identifiers

10846

A5281